A federal district judge in Rochester, N.Y., has given four insulin and diabetes drug manufacturers until Oct. 29 to file a motion to dismiss an upstate New York health center’s lawsuit claiming the manufacturers conspired to stop offering 340B pricing
…
A new federal district judge has been assigned to Pharmaceutical Research and Manufacturers of America’s (PhRMA) lawsuit challenging Arkansas’s 340B nondiscrimination act.
PhRMA’s case, filed on Sept. 29, was initially assigned to U.S. District Judge Lee Rudofsky, a Trump appointee.
…
A federal appeals court is considering some South Carolina Walgreens customers’ claims that Walgreens, in its capacity as a 340B contract pharmacy and as a 340B contract pharmacy third-party administrator (TPA), violated their privacy rights under South Carolina law.
The
…
Pharmaceutical Research and Manufacturers of America (PhRMA) asked a federal district court yesterday to rule that Arkansas’s 340B nondiscrimination act does not require drug manufacturers “to offer price discounts under the 340B program to contract pharmacies in Arkansas.”
PhRMA also
…
A recent U.S. Supreme Court ruling about administrative law judges who hear patent disputes confirms that rules establishing the 340B program’s administrative dispute resolution (ADR) process are constitutional, government lawyers told a federal district judge this month.
Under the 340B
…
A federal district judge this week gave six hospital groups and a drug industry services provider permission to separately offer their expert advice in drug manufacturer Sanofi’s 340B contract pharmacy lawsuit.
In a friend-of-the-court brief, the hospital groups accused
…
A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.
…
The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to
…
The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (HHS OIG) regarding their refusal to offer 340B discounts to 340B covered
…
*Sign up for news summaries and alerts from 340B Report